Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Q3 2019 Earnings Conference Call - Final Transcript
Nov 05, 2019 • 04:30 pm ET
Good afternoon everyone and welcome to Eloxx Pharmaceutical's Third Quarter 2019 Earnings Webcast and Conference call. [Operator Instructions]
At this time I would like to turn the call over to Barbara Ryan Eloxx's Investor Relations Officer. Please begin.
Thank you operator. Welcome and thank you for joining us this afternoon for a review of Eloxx Pharmaceuticals Third Quarter 2019 Financial Results and Business Updates. Joining me this afternoon are Robert Ward Chairman and Chief Executive Officer of Eloxx Pharmaceuticals; Dr. Greg Williams our Chief Operating Officer; Dr. Tom Haverty our Chief Medical Officer; and Greg Weaver our Chief Financial Officer. Before we begin I'd like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors including those discussed in the Risk Factors section in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission and our other reports filed with the SEC. Any forward-looking statements represent our views as of today November 5 2019 only. A replay of this call will be available on the company's website www.eloxxpharma.com following the call.
It is now my pleasure to turn the call over to Robert Ward Chairman and Chief Executive Officer of Eloxx Pharmaceuticals.
Thank you Barbara and welcome to Eloxx's Third Quarter 2019 Earnings Webcast and Conference Call. This was an excellent quarter for E locks. In addition to advancing our clinical and scientific programs. We've also strengthened the leadership team with the appointment of Dr. Tom Haggerty is our chief medical officer. Tom is a Board Certified nephrologist brings an established track record of successful drug development and r&d leadership from senior executive roles from companies like Schering plough and Merck. Tom's been consulted with us for most of the past year, and we're pleased to have him join our team. Today will provide an update on our progress in the clinic with our phase two clinical programs and cystic fibrosis and system houses. As we guided our system gnosis trial has progressed to a point where we've had our first important clinical observations, doctors Williams and haberdashery will share the progress and observations with you in a moment, we will have a steady cadence of additional data and updates as we move through the upcoming quarters.
Just this past week the Eloxx team made 4 scientific presentations about ELX-02 at the North American Cystic Fibrosis Conference including the full results of our MAD study which reinforced the emerging overall favorable tolerability profile of subcutaneous ELX-02. We had an opportunity to hold an investigators' meeting engage with scientific community and to meet with HIT-CF and other potential strategic partners. The expressed level of interest and support for our cystic fibrosis program has really been quite remarkable. Currently our Phase II program consists of 2 trials: one